Sanchita Gupta
Internal Medicine · Ridgewood, NJNPI 1932302924
Payments from drug & device makers
Across 185 payments — averaging $17.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$453
- Johnson & Johnson$416
- Novo Nordisk$339
- Takeda Pharmaceuticals U.S.A., Inc.$290
- Zimmer Biomet$173
- Siemens Medical Solutions USA, Inc.$167
- plus $1K from 28 others
What the payments were for
- Food & beverage$3,171100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $453 |
| Johnson & Johnson(2 entities) | 24 | $416 |
| Novo Nordisk | 16 | $339 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $290 |
| Zimmer Biomet | 1 | $173 |
| Siemens Medical Solutions USA, Inc. | 1 | $167 |
| Amgen | 12 | $160 |
| UOC USA Inc | 2 | $149 |
| AstraZeneca | 8 | $123 |
| Boehringer Ingelheim | 6 | $84 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Merck | 5 | $76 |
| Medtronic | 2 | $69 |
| Pfizer | 4 | $69 |
| Lilly USA, LLC | 4 | $59 |
| GSK | 3 | $46 |
| Xeris Pharmaceuticals, Inc. | 3 | $44 |
| Bausch Health US, LLC | 3 | $42 |
| Madrigal Pharmaceuticals | 2 | $40 |
| Ardelyx, Inc. | 2 | $33 |
| Regeneron Healthcare Solutions, Inc. | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| QOL Medical, LLC | 1 | $25 |
| IBSA Pharma Inc. | 1 | $24 |
| Vifor Pharma, Inc. | 1 | $20 |
| Blueprint Medicines Corporation | 1 | $20 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Biocon Biologics Inc | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Fresenius Kabi USA, LLC | 1 | $15 |
| UCB, Inc. | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Gilead | 1 | $14 |
| Braintree Laboratories, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ROSA$173
- NAEOTOM Alpha$167
- U2, Conformity, U-Motion II and USTAR II$126
- RYBELSUS$125
- VRAYLAR$100
How this compares
$3,182 in reported general payments places this provider in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 55 | $67,864 |
| EliquisApixaban | 45 | $43,231 |
| JanuviaSitagliptin Phosphate | 23 | $37,303 |
| JardianceEmpagliflozin | 21 | $31,428 |
| XareltoRivaroxaban | 23 | $30,474 |
| RybelsusSemaglutide | 11 | $28,599 |
| OxycontinOxycodone Hcl | 12 | $9,796 |
| Valsartan | 208 | $6,639 |
| SynthroidLevothyroxine Sodium | 47 | $3,599 |
| Atorvastatin Calcium | 317 | $3,263 |
| Rosuvastatin Calcium | 258 | $3,242 |
| Metoprolol Succinate | 193 | $2,981 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 67 | $2,817 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 13 | $2,017 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $2,017 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $59 | $67,86455 claims |
| PfizerEliquis | $69 | $43,23145 claims |
| MerckJanuvia | $76 | $37,30323 claims |
| Boehringer IngelheimJardiance | $84 | $31,42821 claims |
| Johnson & JohnsonXarelto | $416 | $30,47423 claims |
| Novo NordiskRybelsus | $339 | $28,59911 claims |
| AbbVieSynthroid | $453 | $3,59947 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Ridgewood
- Sanjiv SharmaToms River$33.9M
- Jeffrey CarsonNew Brunswick$13.8M
- Samer HaddadHamilton$6.8M
- Magdy ShenoudaWall$3.7M
- Samar HameedLivingston$3.6M
- Jane RohlfTrenton$2.7M
- Mohammed NisarEdison$2.6M
- Michael CasserNew Milford$2.2M
- Sumitha ReddyHamilton$2M
- Helio PedroNewark$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.